Analysis Tools|
Allele Symbol Allele Name Allele ID |
Tcf3+ wild type MGI:2432259 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Summary |
15 genotypes
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• B220+IgM B cells are reduced to 58% compared to 64% in wild-type mice
|
|
• B220+IgM B cells are reduced to 58% compared to 64% in wild-type mice
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• B cell numbers reduced by half in the spleen but not the bone marrow
|
|
• B cell numbers reduced by half in the spleen but not the bone marrow
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• mice exhibit a mild defect in adult B cell lymphopoiesis
|
|
• mice exhibit a mild defect in adult B cell lymphopoiesis
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
| N |
• mice have a normal lifespan
|
| N |
• mice exhibit no abnormalities in peripheral blood
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• the IgM+IgD- cell population is significantly reduced
• the IgM+IgD+ cell population is increased in the bone marrow
• the fraction of B cells expressing Ig-lambda is reduced
|
|
• the fraction of pre-B cells is reduced about 2 fold
|
|
• the IgM+IgD- cell population is significantly reduced
• the IgM+IgD+ cell population is increased in the bone marrow
• the fraction of B cells expressing Ig-lambda is reduced
|
|
• the fraction of pre-B cells is reduced about 2 fold
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• mice exhibit increased penetrance and accelerated acute leukemia development compared to single Tcf3tm1(PBX1)Mlc conditional mutants
|
|
• preleukemic mice show a greater decrease of immature B cells of the Lin-CD19+CD43- fractions compared to Tcf3tm1(PBX1)Mlc conditional mutants, indicating a more severe block of B cell differentiation at this stage of maturation
|
|
• preleukemic mice show expansion of GFP+ progenitor cells of the Lin-CD19+CD43+ fractions at younger ages compared to single Tcf3tm1(PBX1)Mlc conditional mutants, indicating accelerated preleukemic progenitor B cell expansion
|
|
• preleukemic mice show a greater decrease of immature B cells of the Lin-CD19+CD43- fractions compared to Tcf3tm1(PBX1)Mlc conditional mutants, indicating a more severe block of B cell differentiation at this stage of maturation
|
|
• preleukemic mice show a greater decrease of immature B cells of the Lin-CD19+CD43- fractions compared to Tcf3tm1(PBX1)Mlc conditional mutants, indicating a more severe block of B cell differentiation at this stage of maturation
|
|
• preleukemic mice show expansion of GFP+ progenitor cells of the Lin-CD19+CD43+ fractions at younger ages compared to single Tcf3tm1(PBX1)Mlc conditional mutants, indicating accelerated preleukemic progenitor B cell expansion
|
|
• preleukemic mice show a greater decrease of immature B cells of the Lin-CD19+CD43- fractions compared to Tcf3tm1(PBX1)Mlc conditional mutants, indicating a more severe block of B cell differentiation at this stage of maturation
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• mice develop acute leukemia with an incidence of 7% at 12 months of age
• leukemia cells are present in the bone marrow, spleen, lymph nodes and infiltrate multiple organs, including the CNS
• 94% of leukemias have a B cell precursor phenotype
|
|
• in leukemic mice
|
|
• progenitor B cells proliferate extensively in methylcellulose culture supplemented with IL-7, SCF, and FLT3 and are severely compromised in the their ability to differentiate into CD43- cells compared with progenitor B cells from controls indicating enhanced proliferation of progenitor B cells
|
|
• mice show perturbed early B cell progenitor cell differentiation
|
|
• leukemic blasts are arrested at the pro/pre-B stage of B cell precursor differentiation
|
|
• in leukemic mice
|
|
• a lower percentage of B cells are seen in the peripheral blood over a 30 week period in healthy preleukemic mice
|
|
• decrease in immature and recirculating B cells in the bone marrow in healthy preleukemic mice
|
|
• leukemic mice present with leukocytosis
|
|
• enhanced proliferation of progenitor B cells
• preleukemic mice irradiated sublethally to deplete the endogenous B cell populations show regeneration of B cell progenitors with a dramatic expansion of B220lo progenitor cell population indicating enhanced B cell progenitor self-renewal
|
|
• in leukemic mice
|
|
• progenitor B cells proliferate extensively in methylcellulose culture supplemented with IL-7, SCF, and FLT3 and are severely compromised in the their ability to differentiate into CD43- cells compared with progenitor B cells from controls indicating enhanced proliferation of progenitor B cells
|
|
• mice show perturbed early B cell progenitor cell differentiation
|
|
• leukemic blasts are arrested at the pro/pre-B stage of B cell precursor differentiation
|
|
• a lower percentage of B cells are seen in the peripheral blood over a 30 week period in healthy preleukemic mice
|
|
• decrease in immature and recirculating B cells in the bone marrow in healthy preleukemic mice
|
|
• leukemic mice present with leukocytosis
|
|
• enhanced proliferation of progenitor B cells
• preleukemic mice irradiated sublethally to deplete the endogenous B cell populations show regeneration of B cell progenitors with a dramatic expansion of B220lo progenitor cell population indicating enhanced B cell progenitor self-renewal
|
|
• in leukemic mice
|
|
• in leukemic mice
|
|
• in leukemic mice
|
|
• in leukemic mice
|
Mouse Models of Human Disease |
DO ID | OMIM ID(s) | Ref(s) | |
| acute lymphoblastic leukemia | DOID:9952 |
OMIM:247640 OMIM:613065 |
J:226241 | |
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• within 6 months, pIpC-treated mice die of leukemia
|
|
• pIpC-treated mice develop acute B-lineage leukemia by 6 months of age unlike control mice
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
| N |
• pIpC-treated mice have a normal lifespan
|
|
• mice treated with pIpC and Moloney murine leukemia virus (MMLV) exhibit increased morbidity and mortality with all mice dying by 6 months of age unlike with similarly treated Tcf3tm1(TCF3/HLF)Homy heterozygotes
|
| N |
• pIpC-treated mice exhibit no abnormalities in peripheral blood
|
|
• pIpC-treated mice exhibit an increase in B cell precursors in the bone marrow compared with similarly treated Tcf3tm1(TCF3/HLF)Homy heterozygotes
|
|
• pIpC-treated mice exhibit an increase in B cell precursors in the bone marrow compared with similarly treated Tcf3tm1(TCF3/HLF)Homy heterozygotes
|
|
• mice treated with pIpC and Moloney murine leukemia virus (MMLV) exhibit increased morbidity and mortality with all mice dying by 6 months of age unlike with similarly treated Tcf3tm1(TCF3/HLF)Homy heterozygotes
• mice treated with pIpC and MMLV develop only acute B-progenitor and lineage marker negative leukemias as early as 2.6 months compared with similarly treated Tcf3tm1(TCF3/HLF)Homy heterozygotes that develop T cell leukemias at 4 to 6 months
|
|
• pIpC-treated and Moloney murine leukemia virus (MMLV)-exposed mice develop microthrombi
|
|
• pIpC-treated mice exhibit an increase in B cell precursors in the bone marrow compared with similarly treated Tcf3tm1(TCF3/HLF)Homy heterozygotes
|
|
• pIpC-treated mice exhibit an increase in B cell precursors in the bone marrow compared with similarly treated Tcf3tm1(TCF3/HLF)Homy heterozygotes
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• mice develop acute leukemia with an incidence of 53% at 12 months of age
• leukemia cells are present in the bone marrow, spleen, lymph nodes and infiltrate multiple organs, including the CNS
• 94% of leukemias have a B cell precursor phenotype
|
|
• in leukemic mice
|
|
• leukemic blasts are arrested at the pro/pre-B stage of B cell precursor differentiation
|
|
• in leukemic mice
|
|
• a lower percentage of B cells are seen in the peripheral blood over a 30 week period in healthy preleukemic mice
|
|
• decrease in immature and recirculating B cells in the bone marrow in healthy preleukemic mice
|
|
• leukemic mice present with leukocytosis
|
|
• in leukemic mice
|
|
• leukemic blasts are arrested at the pro/pre-B stage of B cell precursor differentiation
|
|
• a lower percentage of B cells are seen in the peripheral blood over a 30 week period in healthy preleukemic mice
|
|
• decrease in immature and recirculating B cells in the bone marrow in healthy preleukemic mice
|
|
• leukemic mice present with leukocytosis
|
|
• in leukemic mice
|
|
• in leukemic mice
|
|
• in leukemic mice
|
|
• in leukemic mice
|
Mouse Models of Human Disease |
DO ID | OMIM ID(s) | Ref(s) | |
| acute lymphoblastic leukemia | DOID:9952 |
OMIM:247640 OMIM:613065 |
J:226241 | |
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• mice develop acute leukemia with an incidence of 59% at 12 months of age
• leukemia cells are present in the bone marrow, spleen, lymph nodes and infiltrate multiple organs, including the CNS
• 94% of leukemias have a B cell precursor phenotype
|
|
• in leukemic mice
|
|
• leukemic blasts are arrested at the pro/pre-B stage of B cell precursor differentiation
|
|
• in leukemic mice
|
|
• a lower percentage of B cells are seen in the peripheral blood over a 30 week period in healthy preleukemic mice
|
|
• decrease in immature and recirculating B cells in the bone marrow in healthy preleukemic mice
|
|
• leukemic mice present with leukocytosis
|
|
• in leukemic mice
|
|
• leukemic blasts are arrested at the pro/pre-B stage of B cell precursor differentiation
|
|
• a lower percentage of B cells are seen in the peripheral blood over a 30 week period in healthy preleukemic mice
|
|
• decrease in immature and recirculating B cells in the bone marrow in healthy preleukemic mice
|
|
• leukemic mice present with leukocytosis
|
|
• in leukemic mice
|
|
• in leukemic mice
|
|
• in leukemic mice
|
|
• in leukemic mice
|
Mouse Models of Human Disease |
DO ID | OMIM ID(s) | Ref(s) | |
| acute lymphoblastic leukemia | DOID:9952 |
OMIM:247640 OMIM:613065 |
J:226241 | |
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• most homozygotes died within two weeks of birth
|
|
• evident after birth
|
|
• 70% reduction in the number of pro-B cells
|
|
• 70% reduction in the number of pro-B cells
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• natural killer cell development is partially rescued in bone marrow
|
|
• absent in most mice
|
|
• absent in most mice
|
|
• absent in most mice
|
|
• natural killer cell development is partially rescued in bone marrow
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• most homozygotes died within two weeks of birth
|
|
• evident after birth
|
|
• 70% reduction in the number of pro-B cells
|
|
• 70% reduction in the number of pro-B cells
|
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO) |
||
|
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support. |
last database update 01/13/2026 MGI 6.24 |
|
|
|
||
